Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing